Laurus Labs has received approval to acquire up to 26% of share capital in Kurnool Renewables, a subsidiary company (special purpose vehicle) of Ecoren Energy India (Ecoren) with an investment of up to Rs 35 crore.
This project will enable the company to access 25.53 MW of renewable wind and solar energy and this investment is being done in order to comply with regulatory requirement for Captive Consumption of Power under Indian Electricity Laws and the Policy of the Government. This acquisition will result in lower electricity costs, ensure a reliable green power supply and getting carbon credits thereby promotes sustainable ESG.
The investment by the company is expected to be completed within a period of 1 year in three stages - 30% within 30 days from the date of execution of agreements; 40% upon placing of orders for major equipment and 30% upon receipt of major equipment to the site. The Board of Directors of the company at its meeting held on March 28, 2025, has, inter alia, approved the same.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1714.25 |
Dr. Reddys Lab | 1149.75 |
Cipla | 1452.70 |
Lupin | 2009.40 |
Zydus Lifesciences | 891.25 |
View more.. |